Hyperthyroidism in cats is highly treatable, but access to the most effective treatment — radioactive iodine therapy — is limited by geography and cost, creating welfare disparities between cats in different circumstances.
Cats with well-managed hyperthyroidism return to near-normal health and quality of life. Those with poorly managed disease deteriorate progressively through cardiac hypertrophy, hypertension, and organ damage. The welfare gap between cats with access to definitive radioactive iodine treatment and those managed with inconsistently-administered daily medication is real and significant. Cost barriers and geographic limitations create treatment access disparities that determine whether cats suffer preventable disease progression.